Pharsight

1. List of Qtern drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186	ASTRAZENECA AB	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method	Jul, 2023 (5 months from now)
US6515117	ASTRAZENECA AB	C-aryl glucoside SGLT2 inhibitors and method	Oct, 2025 (2 years from now)
US7919598	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Dec, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799	ASTRAZENECA AB	Coated tablet formulation and method	Jul, 2025 (2 years from now)
US8501698	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Jun, 2027 (4 years from now)
US8221786	ASTRAZENECA AB	Pharmaceutical formulations containing an SGLT2 inhibitor	Mar, 2028 (5 years from now)
US8716251	ASTRAZENECA AB	Pharmaceutical formulations containing an SGLT2 inhibitor	Mar, 2028 (5 years from now)
US8361972	ASTRAZENECA AB	Pharmaceutical formulations containing an SGLT2 inhibitor	Mar, 2028 (5 years from now)

Exclusivity	Exclusivity Expiration
New Strength (NS)	May 2, 2022
New Indication (I)	May 2, 2022

Market Authorisation Date: 27 February, 2017

Treatment: Treatment of type 2 diabetes mellitus; Method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin; Method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin

Dosage: TABLET;ORAL